• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Complete Guide to Monoclonal Antibody and Granulocyte-Colony Stimulating Factor Biosimilars Approved in the United States and European Union

Article

The Complete Guide to Monoclonal Antibody and Granulocyte-Colony Stimulating Factor Biosimilars Approved in the United States and European Union

Reviewed by Joseph P. Fuhr, Jr., PhD, professor emeritus, Widener University

Note: In the United States, products such as insulin, enoxaparin sodium, and hormones are regulated under the Federal Food, Drug and Cosmetic Act, not under the Public Health Service Act. While follow-ons of these products may be declared biosimilars in other regulatory territories (including the European Union), in the United States, follow-ons of these products are not subject to the Biologics Price Competition and Innovation Act’s pathway for biosimilar approval.

Want to get breaking news of US biosimilar approvals? Sign up for emails from The Center for Biosimilars

®

.

Related Videos
Here are the top 5 biosimilar articles for the week of May 13, 2024.
Jeffrey Casberg, RPh, MS.
The Top 5 Center for Biosimilars Articles for the Week of May 6, 2024.
Here are the top 5 biosimilar articles for the week of April 29, 2024.
Related Content
© 2024 MJH Life Sciences

All rights reserved.